Drug Profile

Research programme: immunotherapy - sigma-tau

Alternative Names: Pentraxin 3; PTX 3

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator sigma-tau SpA
Class Proteins
Mechanism of Action Complement activation stimulants; Cytokine stimulants; Cytomegalovirus replication inhibitors; Transcription factor stimulants; Viral fusion protein inhibitors; Virus internalisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Nov 2017 No recent reports of development identified for preclinical development in Aspergillosis in Italy (Parenteral)
04 Nov 2017 No recent reports of development identified for preclinical development in Cytomegalovirus infections(Prevention) in Italy (Parenteral)
04 Jun 2008 Development of PTX3 is ongoing

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com